Zobrazeno 41 - 50
of 1 548
pro vyhledávání: ''
Autor:
Ruihua Bai, Tianshun Zhang, Yongping Song, Qingxin Xia, Kangdong Liu, Zigang Dong, Qiushi Wang, Xiang Li, Keke Wang, Xiaoyu Chang, Ting Wang, Ann M. Bode, Joohyun Ryu, Wei-Ya Ma
Publikováno v:
Cancer Prevention Research. 12:837-848
Lung cancer is the leading cause of cancer-related death worldwide. However, promising agents for lung cancer prevention are still very limited. Identification of preventive targets and novel effective preventive agents is urgently needed for clinica
Autor:
Takashi Kojima, Masahiro Yasunaga, Kenji Hirotani, Yasutoshi Kuboki, Toshihiko Doi, Takashi Kagari, Yoshikatsu Koga, Naoyuki Maeda, Yasuhiro Matsumura, Mayumi Yamauchi, Shigehiro Koganemaru
Publikováno v:
Molecular Cancer Therapeutics. 18:2043-2050
HER3 is overexpressed in several cancers, including colorectal cancer. Although therapies with anti-HER3 antibodies have been investigated, significant clinical benefits have not been reported. U3-1402 is a novel HER3-antibody–drug conjugate (ADC)
Autor:
Natalie Erdmann, Rodger E. Tiedemann, Ronny Drapkin, M. Herman Chui, Fabrice Sircoulomb, Robert Rottapel, Patricia Shaw, Sasha A. Doodnauth
Publikováno v:
Cancer Research. 79:5536-5549
High-grade serous ovarian carcinoma commonly arises from fallopian tube secretory epithelium and is characterized by a high level of chromosomal instability. To model the acquisition of aneuploidy during early carcinogenesis, chromosome missegregatio
Autor:
Genta Nagae, Kazuhiko Koike, Hayato Nakagawa, Yutaka Midorikawa, Shogo Yamamoto, Kenji Tatsuno, Kyoji Moriya, Tadatoshi Takayama, Mitsuhiko Moriyama, Hiroyuki Aburatani
Publikováno v:
Clinical Cancer Research. 25:6217-6227
Purpose:Hepatitis B viral (HBV) DNA is frequently integrated into the genomes of hepatocellular carcinoma (HCC) in patients with chronic HBV infection (chronic HBV, hereafter), whereas the frequency of HBV integration in patients after the disappeara
Autor:
Jeremy Bobera, Charlotte R. Feddersen, Sarah A. Mullen, Jesse D. Riordan, Lexy S. Wadsworth, Jacob L. Schillo, Adam J. Dupuy, Hayley R. Vaughn, Christopher S. Stipp, Brooke M. Jennings, Andrew P. Voigt, Afshin Varzavand, Eliot Y. Zhu
Publikováno v:
Cancer Research. 79:5074-5087
The use of selective BRAF inhibitors (BRAFi) has produced remarkable outcomes for patients with advanced cutaneous melanoma harboring a BRAFV600E mutation. Unfortunately, the majority of patients eventually develop drug-resistant disease. We employed
Autor:
Thomas Roeder, Lia Burkhardt, Judith Bossen, Line Steen, Iris Bruchhaus, Karin Uliczka, Christine Fink, Mandy Mong-Quyen Mai, Roxana Pfefferkorn, Michael Spohn, Holger Heine
Publikováno v:
Molecular Cancer Therapeutics. 18:1659-1668
Lung cancer is the leading cause of cancer-associated mortality. Mutations in the EGFR gene are among the most important inducers of lung tumor development, but success of personalized therapies is still limited because of toxicity or developing resi
Autor:
Luisa Izzi, H. Wang, Victor Cohen, Christian Couture, Nicole Bouchard, Jason Agulnik, Valerie Higenell, Normand Blais, Lise Tremblay, Cyrla Hoffert, Caroline Rousseau, Mathilde Couetoux du Tertre, Gerald Batist, Razvan Diaconescu, Maud Marques, Suzan McNamara, Vincent Pelsser, Karen Gambaro, Alan Spatz, Archana Srivastava
Publikováno v:
Molecular Cancer Therapeutics. 18:1628-1636
Rearrangements in the anaplastic lymphoma kinase (ALK) gene are found in approximately 5% of non–small cell lung carcinoma (NSCLC). Here, we present a comprehensive genomic landscape of 11 patients with ALK+ NSCLC and investigate its relationship w
Autor:
Tiffany A. Hylkema, Irwin D. Bernstein, Jessica A. Pollard, Michael R. Loken, Todd A. Alonzo, Laura Pardo, Alan S. Gamis, Richard Aplenc, Soheil Meshinchi, Lillian Sung, Robert B. Gerbing, Susana C. Raimondi, Betsy A. Hirsch, Rhonda E. Ries, Leela Sarukkai, Katherine Tarlock, Yi-Cheng Wang, Jason Joaquin
Publikováno v:
Clinical Cancer Research. 25:5038-5048
Purpose: KIT mutations (KIT+) are common in core binding factor (CBF) AML and have been associated with varying prognostic significance. We sought to define the functional and clinical significance of distinct KIT mutations in CBF pediatric AML. Expe
Autor:
Janessa Laskin, Sharlene Gill, Jennifer J. Knox, David F. Schaeffer, Martin R. Jones, Marco A. Marra, Howard John Lim, Daniel J. Renouf, James T. Topham, Steven Gallinger, Hui-Li Wong, Karen Mungall, Julie Ho, Richard A. Moore, Angela Goytain, Malcolm J. Moore, Steven J.M. Jones, Yussanne Ma, Andrew J. Mungall, Laura Williamson, Wei Zhang, Robert E. Denroche, Yaoquing Shen, Michael K.C. Lee, Erin Pleasance, Sara Sadeghi, Gun-Ho Jang, Stephen Yip, Joanna M. Karasinska, Carolyn Reisle, Tony Ng, John Paul McGhie
Publikováno v:
Clinical Cancer Research. 25:4674-4681
Purpose: Gene fusions involving neuregulin 1 (NRG1) have been noted in multiple cancer types and have potential therapeutic implications. Although varying results have been reported in other cancer types, the efficacy of the HER-family kinase inhibit
Autor:
Michael J. Schell, Michael Nebozhyn, W. Jack Pledger, Jiannong Li, Jamie K. Teer, Mingli Yang, Timothy J. Yeatman, Andrey Loboda
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 28:1141-1152
Background: EGFR is a major therapeutic target for colorectal cancer. Currently, extended RAS/RAF testing identifies only nonresponders to EGFR inhibitors (EGFRi). We aimed to develop a mutation signature that further refines drug-sensitive subpopula